- Home
- NBTX vs GOSS Comparison
NBTX vs GOSS Comparison
Compare NBTX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- GOSS
- Stock Information
- Founded
- NBTX 2003
- GOSS 2015
- Country
- NBTX France
- GOSS United States
- Employees
- NBTX N/A
- GOSS N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- GOSS Health Care
- Exchange
- NBTX Nasdaq
- GOSS Nasdaq
- Market Cap
- NBTX 201.9M
- GOSS 212.9M
- IPO Year
- NBTX 2020
- GOSS 2019
- Fundamental
- Price
- NBTX $3.26
- GOSS $0.81
- Analyst Decision
- NBTX Strong Buy
- GOSS Strong Buy
- Analyst Count
- NBTX 1
- GOSS 5
- Target Price
- NBTX $12.00
- GOSS $9.20
- AVG Volume (30 Days)
- NBTX 64.6K
- GOSS 2.3M
- Earning Date
- NBTX 12-31-2024
- GOSS 11-07-2024
- Dividend Yield
- NBTX N/A
- GOSS N/A
- EPS Growth
- NBTX N/A
- GOSS N/A
- EPS
- NBTX N/A
- GOSS N/A
- Revenue
- NBTX $45,220,186.00
- GOSS $105,322,000.00
- Revenue This Year
- NBTX N/A
- GOSS N/A
- Revenue Next Year
- NBTX N/A
- GOSS N/A
- P/E Ratio
- NBTX N/A
- GOSS N/A
- Revenue Growth
- NBTX 526.17
- GOSS N/A
- 52 Week Low
- NBTX $2.76
- GOSS $0.50
- 52 Week High
- NBTX $8.96
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- NBTX 42.55
- GOSS 49.87
- Support Level
- NBTX $3.18
- GOSS $0.76
- Resistance Level
- NBTX $3.69
- GOSS $0.88
- Average True Range (ATR)
- NBTX 0.27
- GOSS 0.08
- MACD
- NBTX 0.07
- GOSS 0.01
- Stochastic Oscillator
- NBTX 56.45
- GOSS 30.48
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.